114 related articles for article (PubMed ID: 38646723)
1.
Qu B; Li X; Ma Y; Wang Y; Han Y; Hou G; Gao F
Dalton Trans; 2024 May; 53(18):7946-7952. PubMed ID: 38646723
[TBL] [Abstract][Full Text] [Related]
2.
Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G
Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065
[TBL] [Abstract][Full Text] [Related]
4. A Novel Small Cyclic Peptide-Based
Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
[TBL] [Abstract][Full Text] [Related]
5. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
6. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Evaluation of Ga-68-Labeled Rhein for Early Assessment of Treatment-Induced Tumor Necrosis.
Zhang A; Wu T; Bian L; Li P; Liu Q; Zhang D; Jin Q; Zhang J; Huang G; Song S
Mol Imaging Biol; 2020 Jun; 22(3):515-525. PubMed ID: 31250330
[TBL] [Abstract][Full Text] [Related]
8. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
11. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
12. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
13. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
[TBL] [Abstract][Full Text] [Related]
14. Radiosynthesis, Biological Evaluation, and Preclinical Study of a
Pirooznia N; Abdi K; Beiki D; Emami F; Arab SS; Sabzevari O; Pakdin-Parizi Z; Geramifar P
Contrast Media Mol Imaging; 2020; 2020():8421657. PubMed ID: 32292304
[TBL] [Abstract][Full Text] [Related]
15. Primary Preclinical and Clinical Evaluation of
Li F; Zhang Z; Cai J; Chen X; Zhou Y; Ma X; Dong Q; Li F; Xi L
Clin Cancer Res; 2020 Mar; 26(6):1318-1326. PubMed ID: 31843751
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of
Liu Q; Cai S; Ye J; Xie Q; Liu R; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1826-1840. PubMed ID: 38319321
[TBL] [Abstract][Full Text] [Related]
17. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of melanocortin-1 receptor (MC1-R) specific
Nagy G; Dénes N; Kis A; Szabó JP; Berényi E; Garai I; Bai P; Hajdu I; Szikra D; Trencsényi G
Eur J Pharm Sci; 2017 Aug; 106():336-344. PubMed ID: 28625749
[TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of a radiogallium-labeled bifunctional radiopharmaceutical, Ga-DOTA-MN2, for hypoxic tumor imaging.
Sano K; Okada M; Hisada H; Shimokawa K; Saji H; Maeda M; Mukai T
Biol Pharm Bull; 2013; 36(4):602-8. PubMed ID: 23546294
[TBL] [Abstract][Full Text] [Related]
20. Development of high-specific-activity (68)Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors.
Cantorias MV; Figueroa SD; Quinn TP; Lever JR; Hoffman TJ; Watkinson LD; Carmack TL; Cutler CS
Nucl Med Biol; 2009 Jul; 36(5):505-13. PubMed ID: 19520291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]